Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines in return for a cash injection of up to ...

Lloyd’s of London will delay its Blueprint Two re-platforming project until at least 2028, with market testing not expected before 2026. CEO Patrick Tiernan admitted the update will frustrate ...